4.6 Review

Intranasal antihistamines and corticosteroids in the treatment of allergic rhinitis: a systematic review and meta-analysis protocol

Journal

BMJ OPEN
Volume 13, Issue 11, Pages -

Publisher

BMJ PUBLISHING GROUP
DOI: 10.1136/bmjopen-2023-076614

Keywords

Immunology; Asthma; Allergy; Chronic airways disease

Ask authors/readers for more resources

This systematic review aims to analyze the effectiveness differences among different intranasal specific medications in the treatment of allergic rhinitis. The study will assess the impact of intranasal antihistamines and corticosteroids on nasal and ocular symptoms as well as quality of life in patients with rhinitis.
IntroductionIntranasal antihistamines and corticosteroids are some of the most frequently used drug classes in the treatment of allergic rhinitis. However, there is uncertainty as to whether effectiveness differences may exist among different intranasal specific medications. This systematic review aims to analyse and synthesise all evidence from randomised controlled trials (RCTs) on the effectiveness of intranasal antihistamines and corticosteroids in rhinitis nasal and ocular symptoms and in rhinoconjunctivitis-related quality-of-life.Methods and analysisWe will search four electronic bibliographic databases and three clinical trials databases for RCTs (1) assessing patients >= 12 years old with seasonal or perennial allergic rhinitis and (2) comparing the use of intranasal antihistamines or corticosteroids versus placebo. Assessed outcomes will include the Total Nasal Symptom Score (TNSS), the Total Ocular Symptom Score (TOSS) and the Rhinoconjunctivitis Quality-of-Life Questionnaire (RQLQ). We will assess the methodological quality of included primary studies by using the Cochrane risk-of-bias tool. Certainty in the body of evidence for the analysed outcomes will be assessed using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach. We will perform a random-effects meta-analysis for each assessed medication and outcome, presenting results as pooled mean differences and standardised mean differences. Heterogeneity will be explored by sensitivity and subgroup analyses, considering (1) the risk of bias, (2) the follow-up period and (3) the drug dose.Ethics and disseminationEthical considerations will not be required. Results will be disseminated in a peer-review journal.PROSPERO registration numberCRD42023416573.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available